Actively Recruiting
Comparing Fixed-Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab for Advanced or Metastatic Melanoma
Led by Regeneron Pharmaceuticals · Updated on 2026-10-26
560
Participants Needed
113
Research Sites
328 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an experimental drug combination of fianlimab and cemiplimab compared to the approved combination of relatlimab and nivolumab in adults with unresectable or metastatic melanoma, a serious skin cancer. The study aims to assess the safety and effectiveness of these treatments, including side effects and how the body responds to the drugs. It is a phase 3 clinical trial designed to compare these regimens directly. Participants receive intravenous doses of either fianlimab plus cemiplimab every 3 weeks or relatlimab plus nivolumab every 4 weeks. The study randomly assigns patients to one of these two treatment groups. Treatment continues while monitoring for response and side effects, with the study lasting up to 72 months for assessing outcomes. During the trial, participants undergo regular evaluations including scans to measure tumor response, blood tests to monitor drug levels and antibodies against the drugs, and assessments of side effects. Researchers collect data on overall survival, disease control, and safety throughout the study period. Follow-up and monitoring may continue for several years to fully understand the treatments impacts.
CONDITIONS
Brief Title
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here